Darmstadt, Germany, April 28, 2025 – Merck (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck to acquire SpringWorks.

德国达姆施塔特，2025年4月28日 —— 领先的科技公司默克（DAX: MRK）与总部位于美国康涅狄格州斯坦福的商业阶段生物制药公司SpringWorks Therapeutics, Inc.（纳斯达克：SWTX），专注于严重罕见病和癌症治疗，今日宣布双方已达成最终协议，默克将收购SpringWorks。

The purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) based on SpringWorks’ cash balance as of December 31, 2024, and a premium of 26% to SpringWorks’ unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025, the day prior to the first market speculation of a potential transaction between Merck and SpringWorks..

每股 47 美元的现金收购价格相当于约 39 亿美元的股权价值，或基于 SpringWorks 截至 2024 年 12 月 31 日的现金余额计算的 34 亿美元（30 亿欧元）的企业价值，并较 SpringWorks 在 2025 年 2 月 7 日（即默克与 SpringWorks 之间潜在交易首次市场猜测的前一天）未受影响的 20 日成交量加权平均价格 37.38 美元溢价 26%。

“The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck as a globally diversified, innovation and technology powerhouse. For our Healthcare sector, it sharpens the focus on rare tumors, accelerates growth, and strengthens our presence in the U.S.,” said Belén Garijo, Chair of the Executive Board and CEO of Merck.

“达成收购SpringWorks的协议是我们积极的投资组合战略中的重要一步，旨在将默克定位为全球多元化、创新与技术的领军者。对于我们的医疗保健部门而言，此举进一步聚焦于罕见肿瘤领域，加速增长，并加强了我们在美国的市场地位。” 默克公司执行董事会主席兼首席执行官贝伦·加里奥表示。

“Beyond this planned transaction, we will continue to explore M&A opportunities across our three complementary business sectors, always with a firm focus on strategic fit, financial robustness, and long-term value creation.”.

“除了此次计划中的交易，我们将继续在三个互补的业务领域探索并购机会，始终坚定地关注战略契合度、财务稳健性和长期价值创造。”

The planned transaction is fully aligned with the business development/M&A priorities of Merck’s Healthcare business as outlined during the company’s Capital Markets Day in October 2024: to continue to pursue external innovation via in-licensing of high-quality compounds at various stages of development and focused acquisitions that promise early value creation.

该计划交易完全符合默克医疗保健业务在2024年10月资本市场日上概述的业务发展/并购优先事项：继续通过在不同发展阶段引入高质量化合物的授权许可以及有望实现早期价值创造的有针对性收购来追求外部创新。

It also fits with the strategic objective of strengthening Merck’s Healthcare presence in the United States, the world’s largest pharmaceutical market..

这也符合加强默克公司在美国这一全球最大医药市场上的医疗保健业务的战略目标。

Upon closing, the business combination will immediately contribute to Merck’s revenues and is expected to be accretive to Merck’s earnings per share pre (EPS pre) in 2027. The acquisition will be funded with available cash and new debt. Beyond this planned transaction, Merck will retain the ability to pursue larger transactions and continue to evaluate opportunities across its three sectors, with Life Science a priority.

在交易完成时，这项业务合并将立即为默克公司带来收入，并有望在2027年对其每股收益（EPS pre）产生增值。此次收购将通过可用现金和新债务进行融资。除了这项计划中的交易，默克将继续保有追求更大规模交易的能力，并持续评估其三大领域的机遇，其中生命科学领域将是优先重点。

Merck is committed to preserving its strong investment grade credit rating..

默克公司致力于保持其强劲的投资级信用评级。

SpringWorks’ rare tumor portfolio, including a marketed first-in-class, systemic standard-of-care therapy for adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection, will accelerate immediate and sustainable revenue growth for Merck.

SpringWorks的罕见肿瘤产品组合，包括已上市的首款用于治疗成人硬纤维瘤的一线系统性标准疗法，以及首个且唯一获批用于治疗无法完全切除的症状性丛状神经纤维瘤（PN）的成人和儿童神经纤维瘤病1型（NF1）疗法，将加速默克公司实现即时且可持续的收入增长。

SpringWorks’ portfolio complements Merck’s progress in rare tumors, with Merck recently exercising an .

SpringWorks的产品组合补充了默克在罕见肿瘤方面的进展，默克最近行使了一项期权。

option for worldwide commercialization rights

全球商业化权利的选择权

for pimicotinib, an investigational therapy developed by Abbisko Therapeutics Co., Ltd. for patients with tenosynovial giant cell tumor (TGCT).

对于由 Abbisko Therapeutics Co., Ltd. 开发的用于治疗腱鞘巨细胞瘤 (TGCT) 患者的在研药物 pimicotinib。

“We have the unique opportunity with SpringWorks to establish a leadership position in rare tumors and build a strong foundation for further investments in this area, where a large unmet medical need exists,” said Peter Guenter, member of the Executive Board and CEO of Healthcare at Merck. “Together, Merck and SpringWorks are the perfect combination to improve outcomes for patients with rare tumors and bring therapeutic innovations to more patients worldwide while building on and reinforcing the early success of SpringWorks in the United States.

默克公司执行董事会成员兼医疗保健首席执行官彼得·根特表示：“通过与SpringWorks合作，我们拥有在罕见肿瘤领域确立领导地位的独特机会，并为在这一存在巨大未满足医疗需求的领域进一步投资奠定坚实基础。” “默克和SpringWorks共同努力，是改善罕见肿瘤患者预后的完美组合，同时能够将治疗创新带给全球更多患者，并在美国巩固和推动SpringWorks的早期成功。”

For Merck, the planned acquisition will create long term, sustainable growth for our Healthcare business. Along with my successor Danny Bar-Zohar, we look forward to completing this strategic transaction and making a meaningful difference for patients whose lives are so profoundly affected by these complex and challenging tumors.”.

对于默克而言，计划中的收购将为我们的医疗保健业务创造长期、可持续的增长。我和我的继任者丹尼·巴尔-佐哈尔期待完成这项战略交易，为那些生活受到这些复杂且具有挑战性的肿瘤深刻影响的患者带来有意义的改变。”

The agreed acquisition provides SpringWorks with an opportunity to expand its reach into markets beyond the U.S. and leverage the breadth of resources of Merck’s global Healthcare organization.

商定的收购为SpringWorks提供了扩展其在美国以外市场范围的机会，并利用默克全球医疗保健组织的广泛资源。

“From the outset, our focus at SpringWorks has been to create transformative solutions for patients suffering from serious diseases. We have successfully launched two best-in-class medicines in the United States, and with the aspiration to deliver our therapies worldwide, our journey is at a pivotal juncture.

“从一开始，我们在 SpringWorks 的重点就是为患有严重疾病的患者创造变革性的解决方案。我们已经在美国成功推出了两款同类最佳药物，并且怀着将我们的疗法推向全球的雄心，我们的旅程正处于一个关键的转折点。

It became clear during our discussions with the Merck team that we share many core values, including a commitment to help more patients with rare tumors live longer, better lives,” said Saqib Islam, CEO of SpringWorks Therapeutics. “We believe that by joining forces with Merck, we are not only creating significant, immediate value for our stakeholders, but we will also be able to leverage their resources and expertise to build a brighter future for the patient communities we seek to serve while also creating new opportunities for SpringWorks employees as part of a global organization.”.

在与默克团队的讨论中，我们明显感受到双方拥有许多共同的核心价值观，包括帮助更多罕见肿瘤患者延长生命、改善生活的承诺。”SpringWorks Therapeutics首席执行官Saqib Islam表示，“我们相信，通过与默克携手合作，不仅为我们的利益相关者创造了重大且即时的价值，还能利用他们的资源和专业知识，为我们希望服务的患者群体构建更光明的未来。同时，这也为SpringWorks员工创造了新的机会，成为一家全球性组织的一部分。”

SpringWorks’ U.S. Food and Drug Administration (FDA)-approved therapy, OGSIVEO(nirogacestat) is a first-in-class therapy that is the systemic standard of care for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. SpringWorks' marketing authorization application (MAA) for nirogacestat is under review with the European Medicines Agency (EMA), with a Committee for Medicinal Products for Human Use (CHMP) decision expected in Q2 2025..

春华制药获得美国食品药品监督管理局（FDA）批准的疗法，OGSIVEO(nirogacestat) 是一种首创的治疗药物，是治疗需要系统治疗的进展性硬纤维瘤成人患者系统标准疗法。SpringWorks 公司针对 nirogacestat 的上市授权申请 (MAA) 正在接受欧洲药品管理局 (EMA) 的审查，预计人用药品委员会 (CHMP) 将于 2025 年第二季度做出决定。

GOMEKLI™ (mirdametinib) is the first and only FDA-approved therapy for the treatment of adult and pediatric patients 2 years of age and older with NF1-PN not amenable to complete resection. The FDA’s February 2025 approval of GOMEKLI was based on positive data from SpringWorks’ Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in a robust objective response rate, deep and durable reductions in tumor volume, and a manageable safety profile.

GOMEKLI™（米达美替尼）是首个也是唯一获得FDA批准的疗法，用于治疗2岁及以上因NF1-PN无法完全切除的成人和儿童患者。FDA于2025年2月批准GOMEKLI是基于SpringWorks公司2b期ReNeu试验的积极数据，该数据显示GOMEKLI治疗带来了显著的客观缓解率、肿瘤体积深度且持久的缩小，以及可控的安全性。

With the approval, SpringWorks was granted a rare pediatric disease priority review voucher by the FDA. The marketing authorisation application for mirdametinib has been validated by the European Medicines Agency (EMA) with a potential approval in 2025. In addition, SpringWorks is advancing its pipeline with additional programs in other tumor settings that are currently underserved..

随着审批的通过，SpringWorks 获得了美国食品药品监督管理局（FDA）授予的罕见儿科疾病优先审查券。Mirdametinib 的上市许可申请已获欧洲药品管理局（EMA）验证，有可能在 2025 年获批。此外，SpringWorks 正在推进其管线中其他目前服务不足的肿瘤领域的更多项目。

The transaction has been unanimously approved, by all those in attendance, by both the Merck and SpringWorks Boards of Directors and is expected to close in the second half of 2025, subject to satisfaction of customary closing conditions, including approval of SpringWorks’ shareholders and receipt of required regulatory approvals..

该交易已获得所有出席会议的人员、默克公司和SpringWorks董事会的一致批准，预计将于2025年下半年完成，但需满足惯例的交割条件，包括SpringWorks股东的批准以及获得所需的监管批准。

J.P. Morgan is acting as exclusive financial advisor and Sullivan & Cromwell LLP is acting as legal counsel to Merck. Centerview Partners LLC and Goldman Sachs & Co. LLC are acting as joint financial advisors to SpringWorks, and Goodwin Procter LLP is acting as SpringWorks’ legal counsel.

摩根大通担任默克的独家财务顾问，苏利文·克伦威尔律师事务所担任默克的法律顾问。Centerview Partners LLC 和高盛有限责任公司担任 SpringWorks 的联合财务顾问，Goodwin Procter LLP 担任 SpringWorks 的法律顾问。